Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on December 21, 2015. The report details a material definitive agreement entered into with Professional Compounding Centers of America, Inc. ("PCCA").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the restructuring of a contractual relationship regarding commission payments.
Material Changes
- New Agreement: On December 21, 2015, the Company entered into a "PCCA Commission Agreement."
- Termination of Prior Agreements: The new agreement replaces and terminates the "PCCA Strategic Alliance Agreement" (dated February 18, 2013) and the "PCCA License Agreement" (dated August 30, 2012).
- Commission Structure: The primary purpose of the new agreement is to specifically identify the "PCCA Member IP" and revise the terms and amounts of commission payments PCCA receives based on the Company's net sales of products utilizing this IP.
Outlook, Risks, and Management Commentary
Management indicates that PCCA retains its right to receive commissions on net sales of products utilizing the PCCA Member IP under the revised terms. The full text of the new agreement is not included in this filing but will be attached as an exhibit to the Company's Annual Report on Form 10-K for the year ended December 31, 2015. No specific risks or contingencies beyond the contractual obligations are detailed in this text.
Investor Verification Checklist
- Verify the specific commission rates and payment terms in the PCCA Commission Agreement once filed as an exhibit to the 2015 Form 10-K.
- Confirm the exact scope of the "PCCA Member IP" identified in the new agreement to assess potential revenue impact.
- Review the Company's 2015 Form 10-K for any financial impact resulting from the termination of the prior agreements.